Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy

Cancer Treatment Reviews

Volumn 50, Issue , 2016, Pages 109-117

  Calvo, Emiliano ^a   Schmidinger, Manuela ^b   Heng, Daniel Y C ^c   Grünwald, Viktor ^d   Escudier, Bernard ^e  

^a Centro Integral Oncológico Clara Campal and START Madrid   (Spain)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c TOM BAKER CANCER CENTRE   (Canada)

^d MHH   (Germany)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

mRCC; Overall survival; Predictive markers; Prognostic markers; Sequential therapy; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CANCER VACCINE; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; D DIMER; DOVITINIB; EVEROLIMUS; FIBRINOGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; LENVATINIB; MICRORNA; NIVOLUMAB; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANILIDE; ANTINEOPLASTIC AGENT; BAP1 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; HISTONE LYSINE METHYLTRANSFERASE; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; SET2 PROTEIN, HUMAN; SULFONAMIDE; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

BAP1 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EXPOSURE; FIBRINOGEN BLOOD LEVEL; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEPHRECTOMY; NEPHRON SPARING SURGERY; OVERALL SURVIVAL; PBRM1 GENE; PERSONALIZED MEDICINE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SETD2 GENE; TREATMENT OUTCOME; VHL GENE; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY;

ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; EVEROLIMUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMIDAZOLES; IMMUNOLOGIC FACTORS; INDAZOLES; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTATION; NIACINAMIDE; NUCLEAR PROTEINS; PHENYLUREA COMPOUNDS; PRECISION MEDICINE; PROGNOSIS; PYRIDINES; PYRIMIDINES; PYRROLES; QUINOLINES; RECEPTORS, CCR4; SIROLIMUS; SULFONAMIDES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84988514088     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.09.002     Document Type: Review

References (71)

1. [1] National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology kidney cancer (version 3.2016), < https://www.nccn.org/professionals/physician_gls/f_guidelines.asp>; 2016 [accessed 6 July, 2016].
2. [2] Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma. European Association of Urology, < http://uroweb.org/guideline/renal-cell-carcinoma/>; 2016 [accessed 6 July, 2016].
3. [3] Escudier, B., Porta, C., Schmidinger, M., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:Suppl 3 (2014), iii49–iii56.
4. [4] Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:34 (2009), 5794–5799.
5. [5] Heng, D.Y., Xie, W., Regan, M.M., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:2 (2013), 141–148.
6. [6] Kroeger, N., Xie, W., Lee, J.L., et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119:16 (2013), 2999–3006.
7. [7] Ko, J.J., Xie, W., Kroeger, N., et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16:3 (2015), 293–300.
8. [8] Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P., Mazumdar, M., Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:1 (2002), 289–296.
9. [9] Porta, C., Levy, A., Hawkins, R., et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med 3 (2014), 1517–1526.
10. [10] Harshman, L.C., Xie, W., Bjarnason, G.A., et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 13:9 (2012), 927–935.
11. [11] Rini, B.I., Cohen, D.P., Lu, D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:9 (2011), 763–773.
12. [12] Rini, B.I., Schiller, J.H., Fruehauf, J.P., et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17:11 (2011), 3841–3849.
13. [13] Motzer, R.J., Escudier, B., Tomczak, P., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14 (2013), 552–562.
14. [14] Rini, B.I., Melichar, B., Ueda, T., et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14:12 (2013), 1233–1242.
15. [15] Rini, B.I., Melichar, B., Fishman, M.N., et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 26:7 (2015), 1372–1377.
16. [16] Armstrong, A.J., George, D.J., Halabi, S., Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 30:27 (2012), 3402–3407.
17. [17] Prinsloo, S., Wei, Q., Scott, S.M., et al. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med 38 (2015), 48–56.
18. [18] Keegan, K.A., Schupp, C.W., Chamie, K., Hellenthal, N.J., Evans, C.P., Koppie, T.M., Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 188:2 (2012), 391–397.
19. [19] Brookman-May, S.D., May, M., Shariat, S.F., et al. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma–results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int 112:7 (2013), 909–916.
20. [20] Wong, M.K., Jonasch, E., Pal, S.K., et al. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother 16 (2015), 805–819.
21. [21] Vergho, D., Kneitz, S., Rosenwald, A., et al. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer, 14, 2014, 25.
22. [22] Teixeira, A.L., Ferreira, M., Silva, J., et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35 (2014), 4057–4066.
23. [23] Zhao, J.J., Chen, P.J., Duan, R.Q., Li, K.J., Wang, Y.Z., Li, Y., Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 7:6 (2014), 3318–3323.
24. [24] Zhao, J., Lei, T., Xu, C., et al. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7–H3. Biochem Biophys Res Commun 438:2 (2013), 439–444.
25. [25] Liu, Q., Rexiati, M., Yang, Y., et al. Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma. Med Oncol, 31(4), 2014, 882.
26. [26] Ricketts, C.J., Hill, V.K., Linehan, W.M., Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One, 9(1), 2014, e85621.
27. [27] Yang, Y.Q., Chen, J., Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients. Genet Mol Res 13:3 (2014), 5011–5017.
28. [28] Erdem, S., Amasyali, A.S., Aytac, O., Onem, K., Issever, H., Sanli, O., Increased preoperative levels of plasma fibrinogen and d dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urol Oncol 32 (2014), 1031–1040.
29. [29] Tan, C., Takayama, T., Takaoka, N., et al. Impact of gender in renal cell carcinoma: the relationship of FABP7 and BRN2 expression with overall survival. Clin Med Insight Oncol 8 (2014), 21–27.
30. [30] Qin, J., Yang, B., Xu, B.Q., et al. Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. Int J Clin Exp Pathol 7:6 (2014), 3235–3244.
31. [31] Brugarolas, J., Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32:18 (2014), 1968–1976.
32. [32] Pena-Llopis, S., Christie, A., Xie, X.J., Brugarolas, J., Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res 73:14 (2013), 4173–4179.
33. [33] Kapur, P., Pena-Llopis, S., Christie, A., et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 14:2 (2013), 159–167.
34. [34] Motzer, R.J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O.e., Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31:30 (2013), 3791–3799.
35. [35] Heng, D.Y., Xie, W., Bjarnason, G.A., et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 117:12 (2011), 2637–2642.
36. [36] Seidel, C., Busch, J., Weikert, S., et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 48 (2012), 1023–1030.
37. [37] Halabi, S., Rini, B., Escudier, B., Stadler, W.M., Small, E.J., Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 120:1 (2014), 52–60.
38. [38] Negrier, S., Bushmakin, A.G., Cappelleri, J.C., et al. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:10 (2014), 1766–1771.
39. [39] Delea, T.E., Khuu, A., Heng, D.Y., Haas, T., Soulieres, D., Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer 107:7 (2012), 1059–1068.
40. [40] Petrelli, F., Barni, S., Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies. Clin Genitour Cancer 11:4 (2013), 385–389.
41. [41] Stein, A., Bellmunt, J., Escudier, B., et al. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol 64:6 (2012), 994–1002.
42. [42] Busch, J., Seidel, C., Goranova, I., et al. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:3 (2014), 563–569.
43. [43] Grunwald, V., McKay, R.R., Krajewski, K.M., et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol, 2015.
44. [44] Gruenwald, V., Lin, X., Kalanovic, D., et al. Early tumor shrinkage (eTS) as a predictive and prognostic factor in metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol, 33, 2015, 4551.
45. [45] Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:2 (2007), 115–124.
46. [46] Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:22 (2009), 3584–3590.
47. [47] Escudier, B., Eisen, T., Stadler, W.M., et al., for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:2 (2007), 125–134.
48. [48] Escudier, B., Eisen, T., Stadler, W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:20 (2009), 3312–3318.
49. [49] Sternberg, C.N., Davis, I.D., Mardiak, J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:6 (2010), 1061–1068.
50. [50] Sternberg, C.N., Hawkins, R.E., Wagstaff, J., et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 49:6 (2013), 1287–1296.
51. [51] Escudier, B., Pluzanska, A., Koralewski, P., et al., for the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:9605 (2007), 2103–2111.
52. [52] Escudier, B., Bellmunt, J., Negrier, S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:13 (2010), 2144–2150.
53. [53] Rini, B.I., Halabi, S., Rosenberg, J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:13 (2010), 2137–2143.
54. [54] Hudes, G., Carducci, M., Tomczak, P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:22 (2007), 2271–2281.
55. [55] Motzer, R.J., Escudier, B., Oudard, S., et al., for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:9637 (2008), 449–456.
56. [56] Motzer, R.J., Escudier, B., Oudard, S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:18 (2010), 4256–4265.
57. [57] Rini, B.I., Escudier, B., Tomczak, P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:9807 (2011), 1931–1939.
58. [58] Eichelberg, C., Vervenne, W.L., De, S.M., et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 68:5 (2015), 837–847.
59. [59] Motzer RJ, Nosov D, Tomczak P, et al. Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib [abstract 364]. In: Presented at the American society of clinical oncology genitourinary cancers symposium, February 14–16, 2013, Orlando, FL.
60. [60] Motzer, R.J., Barrios, C.H., Kim, T.M., et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32:25 (2014), 2765–2772.
61. [61] Knox, J.J., Barrios, C.H., Kim, T.M., et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC [abstract]. J Clin Oncol, 33, 2015, 4554.
62. [62] Hutson, T.E., Escudier, B., Esteban, E., et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32:8 (2013), 760–767.
63. [63] Motzer, R.J., Hutson, T.E., Glen, H., et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:15 (2015), 1473–1482.
64. [64] Choueiri, T.K., Escudier, B., Powles, T., et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1814–1823.
65. [65] Choueiri, T.K., Escudier, B., Powles, T., Tannir, N.M., Mainwaring, P.N., Rini, B.I., Hammers, H.J., Donskov, F., Roth, B.J., Peltola, K., Lee, J.L., Heng, D.Y.C., Schmidinger, M., Agarwal, N., Sternberg, C.N., McDermott, D.F., Aftab, D.T., Hessel, C., Scheffold, C., Schwab, G., Hutson, T.E., Pal, S., Motzer, R.J., Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet, 2016.
66. [66] Motzer, R.J., Porta, C., Vogelzang, N.J., et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:3 (2014), 286–296.
67. [67] Ko, J.J., Choueiri, T.K., Rini, B.I., et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 110 (2014), 1917–1922.
68. [68] Mitchell, A.P., Harrison, M.R., Walker, M.S., George, D.J., Abernethy, A.P., Hirsch, B.R., Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pract 11:6 (2015), 491–497.
69. [69] Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
70. [70] Motzer RJ, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Checkmate 025 phase III trial of nivolumab versus everolimus in advanced renal cell carcinoma: outcomes by key baseline factors and prior therapies [abstract 498]. In: Poster presented at the American society of clinical oncology genitourinary cancers symposium, January 7–9, 2016, San Francisco, CA.
71. [71] Rini B, Stenzl A, Zdrojowy R, et al. Late breaking abstract: results from an open-label, randomized, controlled phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC [abstract 17LBA]. In: Presented at 18th ECCO 40th ESMO congress, September 25–29, 2015, Vienna, Austria.